Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in:

04.09.2024 | Peritoneal Surface Malignancy

Triphasic Learning Curve of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

verfasst von: Yusuf Ciftci, BS, Shannon N. Radomski, MD, Blake A. Johnson, BS, Fabian M. Johnston, MD, MHS, Jonathan B. Greer, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS–HIPEC) is an effective but costly procedure for select patients with peritoneal malignancies. The impact of progression along a learning curve on the cost of these procedures is unknown.

Patients and Methods

We performed a retrospective cohort study of patients undergoing CRS–HIPEC from 2016 to 2022 at a single quaternary center. Our study cohort was temporally divided into four equally sized volume quartiles (A, B, C, and D). We utilized cumulative sum plots and split-group analysis to characterize the institutional learning curve based on cost, operative time, length of stay, and morbidity. Multivariable linear regression was performed to estimate costs after adjusting for covariates. Bivariate analysis was performed using a Kruskal–Wallis test to compare continuous variables and a χ2 test to compare categorical variables.

Results

Of 201 patients, the median age [interquartile range (IQR)] was 57 (47–65) years, 113 (56%) patients were female, 143 (71%) were white, and 107 (53%) had private insurance. Median operating room charge [US$42,639 (US$32,477–54,872), p < 0.001] varied between volume quartiles, peaking in quartile C. Stabilization was achieved for 86 cases for operating room cost, 88 cases for routine cost, 96 cases for length of stay, 103 cases for operative time, 120 cases for intensive care unit length of stay, and 150 cases for overall and serious morbidity. The actual operating room and routine costs were similar to predicted costs at the end of the study period.

Conclusions

The CRS–HIPEC learning curve is triphasic, with cost stability achieved relatively early compared with other markers of surgical proficiency.
Literatur
1.
Rudloff U, Langan R, Mullinax J, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275–84.PubMedPubMedCentralCrossRef
2.
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.PubMedCrossRef
3.
van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.PubMedCrossRef
4.
El Halabi H, Gushchin V, Francis J, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110–4.PubMedCrossRef
5.
Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93.PubMedCrossRef
6.
Squires MH, Staley CA, Knechtle W, et al. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications. Ann Surg Oncol. 2015;22(5):1739–45.PubMedCrossRef
7.
Klos D, Riško J, Kriváčková D, et al. Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system—single centre study. Eur J Surg Oncol. 2020;46(3):607–12.PubMedCrossRef
8.
Naffouje SA, O’Donoghue C, Salti GI. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: a cost-utility analysis of a hospital’s initial experience and reflections on the health care system. J Surg Oncol. 2016;113(5):544–7.PubMedCrossRef
9.
Foster JM, Sleightholm R, Patel A, et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open. 2019;2(6):e186847.PubMedPubMedCentralCrossRef
10.
Gani F, Johnston FM, Nelson-Williams H, et al. Hospital volume and the costs associated with surgery for pancreatic cancer. J Gastrointest Surg. 2017;21(9):1411–9.PubMedCrossRef
11.
Al-Qurayshi Z, Robins R, Hauch A, Randolph GW, Kandil E. Association of surgeon volume with outcomes and cost savings following thyroidectomy: a national forecast. JAMA Otolaryngol Head Neck Surg. 2016;142(1):32–9.PubMedCrossRef
12.
Kennedy GT, Ukert BD, Predina JD, et al. Implications of hospital volume on costs following esophagectomy in the United States. J Gastrointest Surg. 2018;22(11):1845–51.PubMedCrossRef
13.
Birkmeyer JD, Gust C, Dimick JB, Birkmeyer NJ, Skinner JS. Hospital quality and the cost of inpatient surgery in the United States. Ann Surg. 2012;255(1):1–5.PubMedCrossRef
14.
Eappen S, Lane BH, Rosenberg B, et al. Relationship between occurrence of surgical complications and hospital finances. JAMA. 2013;309(15):1599–606.PubMedCrossRef
15.
Ho V, Aloia T. Hospital volume, surgeon volume, and patient costs for cancer surgery. Medical Care. 2008;46(7):718–25.PubMedCrossRef
16.
Schwartz PB, Stahl CC, Vande Walle KA, et al. What drives high costs of cytoreductive surgery and HIPEC: patient, provider or tumor? Ann Surg Oncol. 2020;27(13):4920–8.PubMedPubMedCentralCrossRef
17.
18.
Polanco PM, Ding Y, Knox JM, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol. 2015;22(5):1673–9.PubMedCrossRef
19.
Chidambarasamy ES, et al. Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis. Asian J Surg. 2022;45(2):339–45.PubMedCrossRef
20.
21.
Rajeev R, Klooster B, Turaga KK. Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. J Gastrointest Oncol. 2016;7(1):122–8.PubMedPubMedCentral
22.
Schuitevoerder D, Sherman SK, Izquierdo FJ, Eng OS, Turaga KK. Assessment of the surgical workforce pertaining to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the United States. Ann Surg Oncol. 2020;27(9):3097–102.PubMedCrossRef
23.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.PubMedPubMedCentralCrossRef
24.
25.
Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53(1):175–96.PubMedCrossRef
26.
Ramsay CR, Grant AM, Wallace SA, Garthwaite PH, Monk AF, Russell IT. Assessment of the learning curve in health technologies - a systematic review. Int J Tech. 2000;4:1095–108.
27.
Miskovic D, Ni M, Wyles SM, Tekkis P, Hanna GB. Learning curve and case selection in laparoscopic colorectal surgery: systematic review and international multicenter analysis of 4852 cases. Dis Colon Rectum. 2012;55(12):1300–10.PubMedCrossRef
28.
Bokhari MB, Patel CB, Ramos-Valadez DI, et al. Learning curve for robotic-assisted laparoscopic colorectal surgery. Surg Endosc. 2011;25:855–60.PubMedCrossRef
29.
Santullo F, Abatini C, Attalla El Halabieh M, et al. The road to technical proficiency in cytoreductive surgery for peritoneal carcinomatosis: risk-adjusted cumulative summation analysis. Front Surg. 2022;9:877970.PubMedPubMedCentralCrossRef
30.
Helminen O, Kauppila JH, Saviaro H, et al. Minimally invasive esophagectomy learning curves with different types of background experience. J Thorac Dis. 2021;13(11):6261–71.PubMedPubMedCentralCrossRef
31.
32.
Shyr B, Chen SC, Shyr Y-M, Wang SE. Learning curves for robotic pancreatic surgery-from distal pancreatectomy to pancreaticoduodenectomy. Medicine. 2018;97(45):e13000.PubMedPubMedCentralCrossRef
33.
34.
35.
Shannon NB, Tan GHC, Chia CS, Soo KC, Teo MCC. Biphasic learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: technical competence and refinement of patient selection. Pleura Peritoneum. 2018;3:20180122.PubMedPubMedCentralCrossRef
36.
Andréasson H, Lorant T, Påhlman L, Graf W, Mahteme H. Cytoreductive surgery plus perioperative intraperitoneal chemotherapy in pseudomyxoma peritonei: aspects of the learning curve. Eur J Surg Oncol. 2014;40(7):930–6.PubMedCrossRef
37.
Steffen T, Eden J, Bijelic L, et al. Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: consensus on decision making among international experts. Clin Colorectal Cancer. 2020;19(4):277–84.PubMedCrossRef
38.
Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9–15.PubMedCrossRef
39.
Simkens GA, van Oudheusden TR, Nieboer D, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol. 2016;23(13):4214–21.PubMedCrossRef
40.
Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res. 2017;30(9):259–66.CrossRef
41.
Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.PubMedPubMedCentralCrossRef
42.
Burnett A, Lecompte MA, Trabulsi N, et al. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. World J Surg Oncol. 2019;17(1):83.PubMedPubMedCentralCrossRef
43.
Jo MH, Suh JW, Yun JS, Namgung H, Park DG. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer: 2-year follow-up results at a single institution in Korea. Ann Surg Treat Res. 2016;91(4):157–64.PubMedPubMedCentralCrossRef
44.
Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:1–8.CrossRef
45.
46.
Hallet J, Sutradhar R, Jerath A, et al. Association between familiarity of the surgeon-anesthesiologist dyad and postoperative patient outcomes for complex gastrointestinal cancer surgery. JAMA Surg. 2023;158(5):465–73.PubMedPubMedCentralCrossRef
47.
Dong Y, Zhang Y, Jin C. Comprehensive economic evaluation of enhanced recovery after surgery (ERAS) in hepatectomy. Int J Equity Health. 2021;20(1):245.PubMedPubMedCentralCrossRef
48.
Noba L, Rodgers S, Doi L, Chandler C, Hariharan D, Yip V. Costs and clinical benefits of enhanced recovery after surgery (ERAS) multisite implementation program for colorectal surgery in Alberta. Can J Surg. 2016;59(6):415–21.CrossRef
49.
Mao F, Huang Z. Enhanced recovery after surgery for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis. Front Surg. 2021;8:713171.PubMedPubMedCentralCrossRef
Metadaten
Titel
Triphasic Learning Curve of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
verfasst von
Yusuf Ciftci, BS
Shannon N. Radomski, MD
Blake A. Johnson, BS
Fabian M. Johnston, MD, MHS
Jonathan B. Greer, MD
Publikationsdatum
04.09.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15945-y

Weitere Artikel der Ausgabe 12/2024

Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors

  • Open Access
  • Peritoneal Surface Malignancy

ASO Author Reflections: Comparison of Survival Outcomes Between Total Pharyngolaryngectomy and Chemoradiotherapy for T4aM0 Hypopharyngeal Cancer Using Nationwide Real-World Data

  • ASO Author Reflections

ASO Author Reflections: Rationale to Routinely Retest ER, PR and HER-2/neu Receptor Status in Residual Disease After Neoadjvuant Chemotherapy

  • Open Access
  • ASO Author Reflections

Preoperative Prediction of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors Using a Combined CT Radiomics–Clinical Model

  • Endocrine Tumors

ASO Author Reflections: Pelvic Exenteration for Chinese Patients with Locally Advanced or Recurrent Colorectal Cancer: A Report of 122 Cases

  • ASO Author Reflections

Correction: Recent Advances in Diagnosing and Treating Post-Prostatectomy Urinary Incontinence

  • Correction

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise